Compartment-specific protein interactions in beryllium lung disease
- PMID: 37965231
- PMCID: PMC10641575
- DOI: 10.1183/23120541.00138-2023
Compartment-specific protein interactions in beryllium lung disease
Abstract
The study provides insights into proteins that may be relevant in BeS and CBD. It provides a framework to investigate the global changes in lung compartment-specific inflammatory cells to better understand the potential interplay of proteins in CBD. https://bit.ly/3PLNTXC.
Copyright ©The authors 2023.
Conflict of interest statement
Conflict of interest: L. Li received support for the present manuscript from NIH HHS/USA grants R01ES023826, R01ES033678, R01ES025722, R01ES034767 and K01ES020857. Conflict of interest: I.V. Yang received support for the present manuscript from NIH HHS/USA grants R01ES023826, R01ES033678 and R01ES025722; consulting fees were received from Eleven P15, outside the submitted work; and she is an unpaid Chair for the American Thoracic Society Section on Genetics and Genomics, outside the submitted work. Conflict of interest: L.A. Maier received support for the present manuscript from NIH HHS/USA grants R01ES023826, R01ES033678 and R01ES025722. Conflict of interest: M. Bhargava received support for the present manuscript from NIH HHS/USA grant R01ES025722; and grants or contracts from R01HL153613 (Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis; PI M. Bhargava, MPI Maier), KIN-1902-2001 (A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open Label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis; Site PI M. Bhargava); FSR Pilot Grant (Comprehensive Assessment Of Signal Transduction Pathways in Sarcoidosis; PI M. Bhargava) ATYR1923-C-004 (A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis; Site PI M. Bhargava), Chest Foundation (Inflammatory Protein Panel for Sarcoidosis Diagnosis and Prognosis; PI M. Bhargava), outside the submitted work; and has patents planned, issued or pending (Ingbar D, Rich T, Schumacher R, et al. (2022). Composition and Methods for Treating Pulmonary Edema or Lung Inflammation. American Inventors), outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.
Figures
References
-
- Benjamini Y. Discovering the false discovery rate. J R Stat Soc B 2010; 72: 405–416. doi:10.1111/j.1467-9868.2010.00746.x - DOI
Grants and funding
LinkOut - more resources
Full Text Sources